Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2016 on request of the Sponsor.
On 2 September 2004, orphan designation (EU/3/04/224) was granted by the European Commission to Stragen France SAS, France, for homoharringtonine for the treatment of chronic myeloid leukaemia.
The sponsorship was transferred to ChemGenex Europe SAS, France, in January 2009 and subsequently to Teva Pharma GmbH, Germany, in December 2012.
|Disease / condition||
Treatment of chronic myeloid leukaemia
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.